MedTrace Logo

Cannabinoid Supplementation on Vascular and Cognitive Function

NCT03295903 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-10-23

No results posted yet for this study

Summary

Cannabidiol (CBD) is a bioactive cannabinoid compound in marijuana (cannabis sativa), but unlike Δ9 tetrahydrocannabinol (THC), lacks the psychoactivity effect of THC. Available evidence suggests that there are marked therapeutic CBD effects for diverse disease processes including inflammation, cancers, psychosis, and epileptic seizures. The purpose of this study, in both younger and older healthy humans, is to improve our understanding of how CBD might control and regulate blood vessel health as well as cognitive and exercise performance.

Conditions

  • Diet Modification

Interventions

DIETARY_SUPPLEMENT

Cannabidiol supplement

Subjects will be administered in a double-blinded, randomized and cross-over design

Sponsors & Collaborators

  • Lexaria Bioscience Corp.

    collaborator INDUSTRY

  • University of British Columbia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2021-09-30
Completion
2021-10-01

Countries

  • Canada

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03295903 on ClinicalTrials.gov